Genmab — November 2023
-
Of the 11 patients treated, 7 received ≥1 cycle of GEN3014, and among them, the best overall responses were 1 complete response, 2 very good partial responses, 2 partial responses, 1 minimal response, and 1 stable disease. GEN3014 treatment was associated with a transient reduction in either complement component C2 or total complement lytic activity in all patients, suggesting CDC activity.
-
Det kan meget vel blive den største volume handel på hele året. Uden reel nyheder. Det er sket et par gange den seneste tid. Hmm
-
Jeg har samlet flere op mhp et muligt 10-20% run inden udgangen af året.
-
Min tålmodighed er opbrugt, så jeg har skippet den sidste rest af Genmab. Så må vi se om man skal gå ind igen på et tidspunkt.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind